Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 5th edition, 486 pages

Free download

  Prostate Cancer

  Free Subscription

Articles published in Urol Int

Retrieve available abstracts of 76 articles:
HTML format

Single Articles

    October 2020
  1. TAFURI A, Rizzetto R, Amigoni N, Sebben M, et al
    Predictors of Lymph Node Invasion in Patients with Clinically Localized Prostate Cancer Who Undergo Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: The Role of Obesity.
    Urol Int. 2020 Oct 15:1-8. doi: 10.1159/000510008.
    PubMed     Abstract available

    September 2020
  2. CHEN Y, Lan T
    Molecular Origin, Expression Regulation, and Biological Function of Androgen Receptor Splicing Variant 7 in Prostate Cancer.
    Urol Int. 2020 Sep 21:1-17. doi: 10.1159/000510124.
    PubMed     Abstract available

  3. BERGIUS S, Roine RP, Taari K, Sintonen H, et al
    Health-Related Quality of Life and Survival in Prostate Cancer Patients in a Real-World Setting.
    Urol Int. 2020 Sep 21:1-9. doi: 10.1159/000510319.
    PubMed     Abstract available

    August 2020
  4. FANG WY, Wang PF, Fan YC, Shih HJ, et al
    Clinical Experience of Steroid Switch from Prednisone to Dexamethasone in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate.
    Urol Int. 2020 Aug 13:1-6. doi: 10.1159/000509882.
    PubMed     Abstract available

  5. NESTLER T, Wittersheim M, Schaefer S, Hellmich M, et al
    Prediction of Radioresistant Prostate Cancer Based on Differentially Expressed Proteins.
    Urol Int. 2020 Aug 13:1-12. doi: 10.1159/000509447.
    PubMed     Abstract available

  6. CLEMENTS MB, Abdalla B, Culp SH, Costabile RA, et al
    Prostate Cancer Characteristics in the US Preventive Services Task Force Grade D Era: A Single-Center Study and Meta-Analysis.
    Urol Int. 2020 Aug 6:1-7. doi: 10.1159/000507656.
    PubMed     Abstract available

  7. CELEN S, Gultekin A, Ozlulerden Y, Mete A, et al
    Comparison of 68Ga-PSMA-I/T PET-CT and Multiparametric MRI for Locoregional Staging of Prostate Cancer Patients: A Pilot Study.
    Urol Int. 2020 Aug 4:1-8. doi: 10.1159/000509974.
    PubMed     Abstract available

    July 2020
  8. SAAR M, Linxweiler J, Borkowetz A, Fussek S, et al
    Current Role of Multiparametric MRI and MRI Targeted Biopsies for Prostate Cancer Diagnosis in Germany: A Nationwide Survey.
    Urol Int. 2020 Jul 8:1-10. doi: 10.1159/000508755.
    PubMed     Abstract available

    May 2020
  9. TAFURI A, Sebben M, Pirozzi M, Processali T, et al
    Association between Basal Total Testosterone Levels and Prostate Cancer D'Amico Risk Classes.
    Urol Int. 2020 May 27:1-8. doi: 10.1159/000506525.
    PubMed     Abstract available

  10. SAWAZAKI H, Kitamura Y, Yagi K, Arai Y, et al
    Impact of Androgen Deprivation Therapy on Non-Alcoholic Fatty Liver Disease in Patients with Prostate Cancer: A CT Evaluation.
    Urol Int. 2020 May 12:1-6. doi: 10.1159/000507351.
    PubMed     Abstract available

  11. WESTHOFF N, Ritter M, Maros M, Rassweiler-Seyfried MC, et al
    Prospective Feasibility Study of Single-Shot Antibiotic Prophylaxis in Transrectal Focal Ablation of Prostate Cancer.
    Urol Int. 2020 May 12:1-8. doi: 10.1159/000507123.
    PubMed     Abstract available

  12. HENNENLOTTER J, Neumann T, Perner S, Wagner V, et al
    Impact of Histopathological Prostate Inflammation on Urine-Based Prostate Cancer Prediction Using the Prostate Cancer Gene 3 Score.
    Urol Int. 2020 May 8:1-6. doi: 10.1159/000506885.
    PubMed     Abstract available

    April 2020
  13. KAMEL MG, Istanbuly S, Abd-Elhay FA, Mohamed MYF, et al
    Examined and Positive Lymph Node Counts Are Associated with Mortality in Prostate Cancer: A Population-Based Analysis.
    Urol Int. 2020 Apr 8:1-11. doi: 10.1159/000505410.
    PubMed     Abstract available

    December 2019
  14. MEISSNER VH, Bittner R, Kron M, Schiele S, et al
    Impact of a Changing Population Structure and Clustering of Cancer in Prostate Cancer Patients Depending on a First-Degree Family History.
    Urol Int. 2019 Dec 20:1-8. doi: 10.1159/000504789.
    PubMed     Abstract available

  15. TU X, Liu Z, Zhang C, Chang T, et al
    Diagnostic Role of Magnetic Resonance Imaging-Targeted Biopsy for Prostate Cancer in Biopsy-Naive Men: A Meta-Analysis.
    Urol Int. 2019 Dec 11:1-12. doi: 10.1159/000504028.
    PubMed     Abstract available

    November 2019
  16. LIU R, Zhou J, Xia S, Li T, et al
    Androgen Deprivation Therapy and the Risk of Stroke in Patients with Prostate Cancer: An Updated Systematic Review and Meta-Analysis.
    Urol Int. 2019 Nov 20:1-8. doi: 10.1159/000503906.
    PubMed     Abstract available

    August 2019
  17. ROSENHAMMER B, Niessen C, Rotzinger L, Reiss J, et al
    Oncological Outcome and Value of Postoperative Magnetic Resonance Imaging after Focal High-Intensity Focused Ultrasound Therapy for Prostate Cancer.
    Urol Int. 2019 Aug 29:1-9. doi: 10.1159/000502553.
    PubMed     Abstract available

  18. PORCARO AB, Tafuri A, Sebben M, Novella G, et al
    Prostate Volume Index Is Able to Differentiate between Prostatic Chronic Inflammation and Prostate Cancer in Patients with Normal Digital Rectal Examination and Prostate-Specific Antigen Values <10 ng/mL: Results of 564 Biopsy Naive Cases.
    Urol Int. 2019 Aug 29:1-8. doi: 10.1159/000502659.
    PubMed     Abstract available

  19. MIYOSHI Y, Sakamoto S, Kawahara T, Uemura K, et al
    Correlation between Automated Bone Scan Index Change after Cabazitaxel and Survival among Men with Castration-Resistant Prostate Cancer.
    Urol Int. 2019 Aug 28:1-6. doi: 10.1159/000502655.
    PubMed     Abstract available

    June 2019
  20. DEMIRTAS A, Sonmez G, Tombul ST, Demirtas T, et al
    Comparison of the Upgrading Rates of International Society of Urological Pathology Grades and Tumor Laterality in Patients Undergoing Standard 12-Core Prostate Biopsy versus Fusion Prostate Biopsy for Prostate Cancer.
    Urol Int. 2019 Jun 26:1-6. doi: 10.1159/000501528.
    PubMed     Abstract available

  21. PORCARO AB, Tafuri A, Sebben M, Pirozzi M, et al
    Positive Association between Basal Total Testosterone Circulating Levels and Tumor Grade Groups at the Time of Diagnosis of Prostate Cancer.
    Urol Int. 2019 Jun 4:1-8. doi: 10.1159/000500960.
    PubMed     Abstract available

    May 2019
  22. PORCARO AB, Cacciamani GE, Sebben M, Tafuri A, et al
    Lymph Nodes Invasion of Marcille's Fossa Associates with High Metastatic Load in Prostate Cancer Patients Undergoing Extended Pelvic Lymph Node Dissection: The Role of "Marcillectomy".
    Urol Int. 2019 May 8:1-8. doi: 10.1159/000500330.
    PubMed     Abstract available

    April 2019
  23. FUJIMOTO N, Shiota M, Tomisaki I, Minato A, et al
    Reconsideration on Clinical Benefit of Pelvic Lymph Node Dissection during Radical Prostatectomy for Clinically Localized Prostate Cancer.
    Urol Int. 2019 Apr 30:1-12. doi: 10.1159/000497280.
    PubMed     Abstract available

    February 2019
  24. PORCARO AB, Tafuri A, Sebben M, Cacciamani G, et al
    Low Preoperative Prolactin Levels Predict Non-Organ Confined Prostate Cancer in Clinically Localized Disease.
    Urol Int. 2019 Feb 14:1-9. doi: 10.1159/000496833.
    PubMed     Abstract available

    January 2019
  25. MOSCHINI M, Zamboni S, Mattei A, Baumeister P, et al
    Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?
    Urol Int. 2019 Jan 29:1-8. doi: 10.1159/000493899.
    PubMed     Abstract available

  26. BORKOWETZ A, Renner T, Platzek I, Toma M, et al
    Evaluation of Transperineal Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy Compared to Transrectal Systematic Biopsy in the Prediction of Tumour Aggressiveness in Patients with Previously Negative Biopsy.
    Urol Int. 2019;102:20-26.
    PubMed     Abstract available

  27. ZALESKY M, Stejskal J, Adamcova V, Hrbacek J, et al
    Use of Prostate Specific Antigen Density Combined with Multiparametric Magnetic Resonance Imaging Improves Triage for Prostate Biopsy.
    Urol Int. 2019;103:33-40.
    PubMed     Abstract available

  28. HODHOD A, Oquendo F, Nour H, Kelly R, et al
    The ex vivo and in vivo Characteristics of New DrillCutTM Prostate Morcellator after Holmium Laser Enucleation of the Prostate: A Pilot Study.
    Urol Int. 2019;103:95-101.
    PubMed     Abstract available

  29. ANTONELLI A, Palumbo C, Noale M, Porreca A, et al
    Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR Study).
    Urol Int. 2019;103:8-18.
    PubMed     Abstract available

  30. LEE CU, Sung SH, Jang CT, Kang M, et al
    Cancer Location in Upgrading and Detection after Transperineal Template-Guided Mapping Biopsy for Patients in Active Surveillance and Negative Transrectal Ultrasonography-Guided Prostate Biopsy.
    Urol Int. 2019;103:262-269.
    PubMed     Abstract available

    December 2018
  31. LIU Y, Zhao S, Wang J, Zhu Z, et al
    Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis.
    Urol Int. 2018 Dec 5:1-12. doi: 10.1159/000495512.
    PubMed     Abstract available

    November 2018
  32. LEYH-BANNURAH SR, Zaffuto E, Dell'Oglio P, Tian Z, et al
    Prediction of Complications in Radical Prostatectomy Prostate Cancer Patients: Simulated Annealing versus Co-Morbidity Indexes.
    Urol Int. 2018 Nov 27:1-9. doi: 10.1159/000495071.
    PubMed     Abstract available

  33. FERRO M, Musi G, Serino A, Cozzi G, et al
    Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients.
    Urol Int. 2018 Nov 8:1-8. doi: 10.1159/000494259.
    PubMed     Abstract available

    October 2018
  34. MIYOSHI Y, Ohtaka M, Kawahara T, Ohtake S, et al
    Prediction of Time to Castration-Resistant Prostate Cancer Using Low-Molecular-Weight Protein Tyrosine Phosphatase Expression for Men with Metastatic Hormone-Naive Prostate Cancer.
    Urol Int. 2018 Oct 16:1-6. doi: 10.1159/000493324.
    PubMed     Abstract available

    September 2018
  35. KIM SJ, Lee SW, Ha HK
    Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Me
    Urol Int. 2018 Sep 28:1-10. doi: 10.1159/000493169.
    PubMed     Abstract available

  36. ROSENHAMMER B, Lausenmeyer EM, Mayr R, Burger M, et al
    Holmium Laser Enucleation of the Prostate Provides Similar Incidental Prostate Cancer Detection Rates as Open Prostatectomy: A Matched Pair Analysis.
    Urol Int. 2018 Sep 20:1-5. doi: 10.1159/000492923.
    PubMed     Abstract available

    July 2018
  37. PORCARO AB, Tafuri A, Sebben M, Corsi P, et al
    Positive Association between Preoperative Total Testosterone Levels and Risk of Positive Surgical Margins by Prostate Cancer: Results in 476 Consecutive Patients Treated Only by Radical Prostatectomy.
    Urol Int. 2018;101:1-9.
    PubMed     Abstract available

    June 2018
  38. DARR C, Krafft U, Hadaschik B, Tschirdewahn S, et al
    The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer.
    Urol Int. 2018 Jun 27:1-9. doi: 10.1159/000489891.
    PubMed     Abstract available

    May 2018
  39. LUZZAGO S, Musi G, Catellani M, Russo A, et al
    Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.
    Urol Int. 2018 May 7:1-9. doi: 10.1159/000488772.
    PubMed     Abstract available

    April 2018
  40. PORCARO AB, Tafuri A, Novella G, Sebben M, et al
    Inverse Association of Prostatic Chronic Inflammation among Prostate Cancer Tumor Grade Groups: Retrospective Study of 738 Consecutive Cases Elected to a First Random Biopsy Set.
    Urol Int. 2018 Apr 19. pii: 000488882. doi: 10.1159/000488882.
    PubMed     Abstract available

    March 2018
  41. BRUENDL J, Rothbauer C, Ludwig B, Dotzler B, et al
    Accordance of Online Health Information on Prostate Cancer with the European Association of Urology Guidelines.
    Urol Int. 2018 Mar 7. pii: 000487146. doi: 10.1159/000487146.
    PubMed     Abstract available

    January 2018
  42. BORKOWETZ A, Renner T, Platzek I, Toma M, et al
    Evaluation of Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy in Patients with Low-Risk Prostate Cancer Under Active Surveillance Undergoing Surveillance Biopsy.
    Urol Int. 2018 Jan 16. pii: 000486041. doi: 10.1159/000486041.
    PubMed     Abstract available

  43. TINAY I, Aslan G, Kural AR, Ozen H, et al
    Pathologic Outcomes of Candidates for Active Surveillance Undergoing Radical Prostatectomy: Results from a Contemporary Turkish Patient Cohort.
    Urol Int. 2018;100:43-49.
    PubMed     Abstract available

  44. AL-BAYATI M, Grueneisen J, Lutje S, Sawicki LM, et al
    Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging.
    Urol Int. 2018;100:164-171.
    PubMed     Abstract available

  45. SANCHIS-BONET A, Barrionuevo-Gonzalez M, Bajo-Chueca A, Morales-Palacios N, et al
    Does [-2]Pro-Prostate Specific Antigen Meet the Criteria to Justify Its Inclusion in the Clinical Decision-Making Process?
    Urol Int. 2018;100:146-154.
    PubMed     Abstract available

  46. HASHIMOTO M, Matsumura N, Ohzeki T, Hongo S, et al
    The Change in Neutrophil Lymphocyte Ratio from the First to the Last Repeat Prostate Biopsy Proposed as a Marker of Carcinogenesis.
    Urol Int. 2018;101:74-79.
    PubMed     Abstract available

  47. XIANG C, Liu X, Chen S, Wang P, et al
    Prediction of Biochemical Recurrence Following Radiotherapy among Patients with Persistent PSA after Radical Prostatectomy: A Single-Center Experience.
    Urol Int. 2018;101:47-55.
    PubMed     Abstract available

    December 2017
  48. OLIVER T, Wilson P, Ansell W, Philp T, et al
    A Prospective Audit of Intermittent Anti-Androgen verses Pituitary Blockade Suggests a Bipolar Androgen Type Strategy May Be Safe in Untreated Prostate Cancer.
    Urol Int. 2017 Dec 22. pii: 000485255. doi: 10.1159/000485255.
    PubMed     Abstract available

  49. ALBKRI A, Girier D, Mestre A, Costa P, et al
    Urinary Incontinence, Patient Satisfaction, and Decisional Regret after Prostate Cancer Treatment: A French National Study.
    Urol Int. 2017;100:49-55.
    PubMed     Abstract available

  50. OHLMANN CH, Gross-Langenhoff M
    Efficacy and Tolerability of Leuprorelin Acetate (Eligard(R)) in Daily Practice in Germany: Pooled Data from 2 Prospective, Non-Interventional Studies with 3- or 6-Month Depot Formulations in Patients with Advanced Prostate Cancer.
    Urol Int. 2017 Dec 1. pii: 000479187. doi: 10.1159/000479187.
    PubMed     Abstract available

    November 2017
  51. HAMMERER PG, Wirth MP
    Health-Related Quality of Life in 536 Long-Term Prostate Cancer Survivors after Treatment with Leuprorelin Acetate: A Combined Retrospective and Prospective Analysis.
    Urol Int. 2017 Nov 25. pii: 000479434. doi: 10.1159/000479434.
    PubMed     Abstract available

  52. ARTIBANI W, Porcaro AB, De Marco V, Cerruto MA, et al
    Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review.
    Urol Int. 2017 Nov 21. doi: 10.1159/000481438.
    PubMed     Abstract available

    October 2017
  53. TANG Y, Liu Z, Tang L, Zhang R, et al
    Significance of MRI/Transrectal Ultrasound Fusion Three-Dimensional Model-Guided, Targeted Biopsy Based on Transrectal Ultrasound-Guided Systematic Biopsy in Prostate Cancer Detection: A Systematic Review and Meta-Analysis.
    Urol Int. 2017 Oct 30. doi: 10.1159/000484144.
    PubMed     Abstract available

  54. YOO S, You D, Kim YS, Hong JH, et al
    Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
    Urol Int. 2017 Oct 12. doi: 10.1159/000481265.
    PubMed     Abstract available

    September 2017
  55. ZAPALA P, Dybowski B, Poletajew S, Radziszewski P, et al
    What Can Be Expected from Prostate Cancer Biomarkers? A Clinical Perspective.
    Urol Int. 2017 Sep 15. doi: 10.1159/000479982.
    PubMed     Abstract available

    July 2017
  56. VON HARDENBERG J, Schwartz M, Werner T, Fuxius S, et al
    Oncologic Response and Hospitalization Rate of Patients Receiving Cabazitaxel in the Fourth-Line and Beyond in Castration-Resistant Prostate Cancer: Analysis of a Retrospective Cohort and a Structured Literature Review.
    Urol Int. 2017 Jul 13. doi: 10.1159/000477943.
    PubMed     Abstract available

  57. FAHMY O, Khairul-Asri MG, Hadi SHSM, Gakis G, et al
    The Role of Radical Prostatectomy and Radiotherapy in Treatment of Locally Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.
    Urol Int. 2017 Jul 4. doi: 10.1159/000478789.
    PubMed     Abstract available

    June 2017
  58. BOESEN L, Norgaard N, Logager V, Balslev I, et al
    A Prospective Comparison of Selective Multiparametric Magnetic Resonance Imaging Fusion-Targeted and Systematic Transrectal Ultrasound-Guided Biopsies for Detecting Prostate Cancer in Men Undergoing Repeated Biopsies.
    Urol Int. 2017 Jun 27. doi: 10.1159/000477214.
    PubMed     Abstract available

  59. MIYOSHI Y, Yoneyama S, Kawahara T, Hattori Y, et al
    Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
    Urol Int. 2017 Jun 14. doi: 10.1159/000477131.
    PubMed     Abstract available

    May 2017
  60. PORCARO AB, De Luyk N, Corsi P, Sebben M, et al
    Clinical Factors Predicting Bilateral Lymph Node Invasion in High-Risk Prostate Cancer.
    Urol Int. 2017 May 10. doi: 10.1159/000476039.
    PubMed     Abstract available

    April 2017
  61. CHOI H, Cho S, Bae JH, Lee SE, et al
    Characteristics of Prostate Cancer by Opportunistic Screening in Korean Men with a Prostate-Specific Antigen Level Less Than 4.0 ng per Milliliter.
    Urol Int. 2017 Apr 11. doi: 10.1159/000454886.
    PubMed     Abstract available

    February 2017
  62. MOSCHINI M, Shariat SF, Freschi M, Soria F, et al
    Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer.
    Urol Int. 2017 Feb 1. doi: 10.1159/000454736.
    PubMed     Abstract available

    January 2017
  63. ORBERGER M, Palisaar J, Roghmann F, Mittelstadt L, et al
    Association between the Surgical Apgar Score and Perioperative Complications after Radical Prostatectomy.
    Urol Int. 2017;98:61-70.
    PubMed     Abstract available

  64. KLEIN J, de Gorski A, Benamran D, Vallee JP, et al
    Transrectal Ultrasound-Guided Prostate Biopsy for Cancer Detection: Performance of 2D-, 3D- and 3D-MRI Fusion Targeted Techniques.
    Urol Int. 2017;98:7-14.
    PubMed     Abstract available

  65. HAAS M, Gunzel K, Miller K, Hamm B, et al
    Is the Ellipsoid Formula the New Standard for 3-Tesla MRI Prostate Volume Calculation without Endorectal Coil?
    Urol Int. 2017;98:49-53.
    PubMed     Abstract available

  66. GUNZEL K, Haas M, Maxeiner A, Stephan C, et al
    Predictive Parameters Identifying Men Eligible for a Sole MRI/Ultrasound Fusion-Guided Targeted Biopsy without an Additional Systematic Biopsy.
    Urol Int. 2017;98:15-21.
    PubMed     Abstract available

  67. SCHIFFMANN J, Larcher A, Sun M, Tian Z, et al
    Differences in Patient Characteristics among Men Choosing Open or Robot-Assisted Radical Prostatectomy in Contemporary Practice - Analysis of Surveillance, Epidemiology, and End Results Database.
    Urol Int. 2017;98:40-48.
    PubMed     Abstract available

  68. MENDEZ-RUBIO S, Salinas Casado J, Virseda Chamorro M, Gutierrez Martin P, et al
    Post Pelvic Radiotherapy Affectation of the Lower Urinary Tract Peripheral Innervation in Men.
    Urol Int. 2017;98:85-88.
    PubMed     Abstract available

  69. FOCARDI M, Bonelli A, Pinchi V, Vittori G, et al
    Hemidiaphragm Paralysis after Robotic Prostatectomy: Medical Malpractice or Unforeseeable Event?
    Urol Int. 2017;98:241-244.
    PubMed     Abstract available

  70. HIRASAWA Y, Yoshioka K, Nasu Y, Yamamoto M, et al
    Impact of Surgeon and Hospital Volume on the Safety of Robot-Assisted Radical Prostatectomy: A Multi-Institutional Study Based on a National Database.
    Urol Int. 2017;98:334-342.
    PubMed     Abstract available

  71. PEETERS C, Ponette D, van Poppel H
    Salvage Pelvic Lymph Node Dissection after Radical Prostatectomy for Biochemical and Lymph Node Recurrence.
    Urol Int. 2017;98:367-369.
    PubMed     Abstract available

  72. LAI P, Luo M, Hu G, Liu H, et al
    Primary Urothelial Carcinoma of the Prostate with Glandular Differentiation: A Case Report.
    Urol Int. 2017;98:370-372.
    PubMed     Abstract available

    January 2016
  73. SARKAR D, Ekwueme K, Parr N
    Patient-Reported Experience of Modified Transperineal Template Guided Saturation Biopsy Under General Anaesthesia and without Prophylactic Catheterisation.
    Urol Int. 2016;96:479-83.
    PubMed     Abstract available

  74. ANGULO JC, Lopez JI, Dorado JF, Sanchez-Chapado M, et al
    A DNA Hypermethylation Profile Independently Predicts Biochemical Recurrence Following Radical Prostatectomy.
    Urol Int. 2016;97:16-25.
    PubMed     Abstract available

  75. ROSENKRANTZ AB, Lepor H, Huang WC, Taneja SS, et al
    Practical Barriers to Obtaining Pre-Biopsy Prostate MRI: Assessment in Over 1,500 Consecutive Men Undergoing Prostate Biopsy in a Single Urologic Practice.
    Urol Int. 2016;97:247-8.

  76. SCHIFFMANN J, Haese A, Lenz J, Heinzer H, et al
    Differences in Patient Characteristics Among Men Choosing Open or Robot-Assisted Radical Prostatectomy in Contemporary Practice at a European High-Volume Center.
    Urol Int. 2016;97:8-15.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.